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Abstract
Although many genetic factors have been successfully identified for human diseases in genome-wide association
studies, genes discovered to date only account for a small proportion of overall genetic contributions to many
complex traits. Association studies have difficulty in detecting the remaining true genetic variants that are either
common variants with weak allelic effects, or rare variants that have strong allelic effects but are weakly associated
at the population level. In this work, we applied a goodness-of-fit test for detecting sets of common and rare
variants associated with quantitative or binary traits by using whole genome sequencing data. This test has been
proved optimal for detecting weak and sparse signals in the literature, which fits the requirements for targeting
the genetic components of missing heritability. Furthermore, this p value-combining method allows one to
incorporate different data and/or research results for meta-analysis. The method was used to simultaneously
analyse the whole genome sequencing and genome-wide association studies data of Genetic Analysis Workshop
18 for detecting true genetic variants. The results show that goodness-of-fit test is comparable or better than the
influential sequence kernel association test in many cases.
Background
According to the Catalog of Genome-Wide Association
Studies updated by the National Human Genome
Research Institute, approximately 7260 single-nucleotide
polymorphisms (SNPs) have been identified for 770
traits in 1360 publications as of November 2012. How-
ever, researchers believe that a significant proportion of
heritability of many complex traits is still missing [1,2].
The remaining genetic variants to be detected are either
common variants with small allelic effects, or rare var-
iants with relatively strong allelic effects. In both cases,
the genetic effects are weak at the population level.
Furthermore, only a small proportion of the avalanche
of candidate variants are likely associated with a trait,
which is a problem closely related to sparse signal dis-
covery in statistics. It is very challenging to detect weak
and sparse genetic effects via association.
To address this issue, we adopt a goodness-of-fit test
(GOFT) [3] that has been proved to be optimal under a
Gaussian means model [4]. That is, the boundary of the
reliable detection of this method reaches the lowest possi-
bility among all statistical tests when the signals are weak
and sparse. Because the Gaussian means model is asymp-
totically equivalent to regression models [5], the GOFT is
promising in detecting weak and sparse genetic effects
through regression model fitting. In this work, we illus-
trate how to apply the test to whole genome sequencing
(WGS) data by using the Genetic Analysis Workshop 18
(GAW18) data. The method is assessed under various rare
variant collapsing strategies, and compared with the
sequence kernel association test (SKAT) [6]. Moreover,
because GOFT is a method combining p values, it has the
potential to be used as a meta-analysis for incorporating
data from different sources. We apply GOFT to simulta-
neously analyse WGS data and genome-wide association
studies (GWAS) data for detecting genetic loci associated
with systolic blood pressure (SBP). The results show that
even without the sophisticated weighting scheme, GOFT
is comparable to, and sometimes better than, SKAT under
its best weighting scheme. In addition, at small p value* Correspondence: zheyangwu@wpi.edu
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cutoffs, the GOFT meta-analysis provides higher power
than that when only WGS data is used.
Methods
Method 1: sequence kernel association test
Sequence kernel association test (SKAT) [6] is a super-
vised and flexible test for the associations between sets of
genetic variants and a continuous or dichotomous trait.
Through adjusting the variance of the random effect
coefficients of the genetic variants, SKAT can consider
different weights for different variants in contributing to
the response trait. Typically, the rare variants are
assigned with larger weights than the common variants
based on the rare variant-common disease model [7]. We
use the R package SKAT [8] for the WGS data analysis.
Method 2: goodness-of-fit test
The problem of determining the associations between a
set of genetic variants and the trait can be viewed as a
multiple hypotheses testing problem. Under the null
hypothesis that there is no genetic association, the p
value from each genetic variant follows a uniform (0,1)
distribution. So testing a group of variants can be consid-
ered as a GOFT that measures the consistency between
the empirical distribution of the observed p values and
the uniform distribution. Here we adopt a GOFT from
Berk and Jones [3], which was proposed from large devia-
tion theory, and then was proved optimal in detecting
weak and sparse signals [4]. Let p(1) ≤ . . . ≤ p(L) be the
sorted p values from L individual variants and the trait.
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0, if 0 ≤ t ≤ x ≤ 1,
+∞, Otherwise.
(1)
Comparing with many p value-based SNP-set testing
methods that sum up all p values together in certain for-
mulas [9], GOFT looks for the most representative p value
to the SNP set. At the same time, unlike the minimal
p value method that fixes the smallest p value to represent
the set, GOFT adapts to the signal pattern through the
maximization procedure. Such adaptation is critical
because the p value of a true association is not necessarily
the minimal value, especially when true associations are
sparse and weak [4]. Another advantage is that the GOFT
statistic only requires information from a set of p values to
work, so it can be flexibly applied to different genetic stu-
dies based on the corresponding appropriate p values, or
to meta-analyses that incorporate various data sources.
A permutation test can be applied to accommodate
the various sizes of variant sets and the linkage
disequilibrium structures among the variants. Specifi-
cally, let Gs and Gsm, s = 1, . . . , S, m = 1, . . . ,M, denote
the GOFT statistics of the sth genome segment window
from the original data and from the mth permutation of
the genotype data, respectively. The empirical p value
for the sth window is ps = # {Gsm ≥ Gs,m = 1, . . . ,M} /M.
The number of permutations M = 1000 was used in the
following data analysis.
Collapsing of rare variants
For the association study of complex diseases based on
WGS data, a major challenge is to address rare variants
that have weak statistical association as a result of small
allele frequency. The GOFT is asymptotically optimal
for weak and sparse signals, and is a right fit in this sce-
nario. At the same time, because the effects of missense
rare alleles are mostly in the same deleterious direction
[10], collapsing the rare variant before GOFT is likely
more efficient [11]. Furthermore, because common and
rare variants contribute to complex diseases, it is good
to combine information from both to facilitate the
detection of associated genome segments. Following a
literature work [12], we collapse rare single-nucleotide
variants (SNVs) that allocate between adjacent common
SNVs by summation of their genotype. Then the p
values for associations of both collapsed rare variants
and common variants are obtained and fed into GOFT
test statistic in equation (1) to study the overall signifi-
cance of variant groups.
Results
For evaluating the above association tests, we used the
WGS “dose” file of 1,215,399 SNVs and the GWAS file
of 65,519 SNVs on chromosome 3 as the genotype data.
The quantitative trait was the SBP for the 142 indepen-
dent individuals who had no missing genotype. To
assess how the SNV group’s size may have affected the
performance of these tests, we split chr3 into segments
of fixed windows with 1 of 3 widths: 10 kilobase pairs
(kbp), 100 kbp, and 500 kbp. Respectively at those 3
levels, the grouping strategy resulted in 19,472, 1950,
and 391 windows, among which 87, 37, and 20 windows
contained true SNVs that were either nonsynonymous
or regulatory to SBP according to the GAW18 simula-
tion [13]. The true windows and the 200 simulation
replicates were used to evaluate power and type I error
rate. We defined a SNV as a rare variant if it had a
minor allele frequency less than 5%. The knowledge of
the simulated true SNVs was only used for evaluating
the power of the association tests, not for designing the
tests and the data analysis strategies.
For GOFT, we assessed its type I error rates as esti-
mated based on the false-positive rate of the 19,385
false 10 kbp windows on chr3 over a sequence of
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cutoffs. The type I error rate was well controlled (results
are available upon request). Figure 1 shows the assess-
ment for the power of GOFT in detecting overall
genetic associations, which was estimated by the true-
positive rate of true-association windows based on
GAW18 simulation replicate 1. We considered various
window sizes with and without rare variant collapsing.
Larger windows provided higher power at large cutoffs,
but not at the small p values that are often used in prac-
tice. This is because large windows likely had more
noise variants, which diluted the signals from true var-
iants, and thus were harder to get very small p values.
Meanwhile, rare variant collapsing did help to increase
the power in general.
Under the window size of 10 kbp, we assessed SKAT
with different strategies of weighting variants: flat
weight, Beta(1, 1), Beta(0.5, 0.5), Beta(1, 25), and logistic
(0.07, 150). Figure 2 shows the power of detecting the
87 true 10 kbp windows on chr3 over a variety of p
value cutoffs. The Beta(1, 25) and logistic weights per-
formed better for small p value cutoffs. Figure 2 also
shows that GOFT was similar to the best SKAT setups
for small p values. In fact, GOFTs had a larger area
under the curve than SKATs when comparing their
whole receiver operating characteristic (ROC) curves
(results are available upon request).
To study the performance in detection of various pat-
terns of genetic effects, we compared the power of
GOFT and logistic-weight SKAT in detecting each of all
87 true 10-kbp windows on chr3. The power was esti-
mated by the true-positive rate of a true window among
200 replicates. There are 3 patterns of comparisons:
GOFT was better in 42 windows (Figure 3, left panel),
SKAT was better in 27 windows (Figure 3, middle
panel), and both were similar. Figure 3 illustrates exam-
ples of these comparisons based on the ROC curve
(complete results are available upon request). GOFT
seems better overall, but the comparison is not very sig-
nificant (42 vs. 27, with a p value = 0.10). The type I
error rate was well controlled here (results available
upon request).
Because GOFT only requires p values as the input, it
has the potential to be used in a meta-analysis that
incorporates data from different studies. Here we evalu-
ated how much useful information the GWAS data
could contribute to the WGS study. By mapping the
“rs” IDs to the chromosome report from dbSNP, we cal-
culated the p values of 65,519 GWAS SNVs on chr3.
Figure 1 Power of GOFT for different window sizes with or without collapsing variants. Power is estimated by the true-positive rate of
true-association windows on chr3 based on GAW18 simulation replicate 1.
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On average, 3.4 GWAS SNVs were added into each
window (approximately a 5% increase). Figure 4 shows
that the type I error rate control, after adding the
GWAS SNVs, was still good (left panel) and that adding
GWAS data helped to improve the power of GOFT in
detecting true 10-kbp windows on chr3 in general.
Discussion
We attempt to address the low power issue of associa-
tion tests for WGS data from 2 aspects. First, we prefer
to use tests specially designed for detecting weak and
sparse genetic effects. For this purpose, the GOFT is
asymptotically optimal in the sense that its asymptotic
Figure 2 Power of GOFT and SKAT under different weighting schemes. Power is estimated by the true-positive rate of 87 true 10-kbp
windows on chr3.
Figure 3 Comparison patterns between GOFT and SKAT for detecting true windows. Left: Window 4799 illustrates a case where GOFT is
better. Middle: Window 5701 is an example where SKAT with logistic-weight is better. Right: Window 13613 is an example of both methods
being similar.
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detection boundary is one of the lowest boundaries
among all statistical methods. If signals are weaker or
sparser than this boundary, no statistical methods
would work well. Second, we try to borrow information
from other data sets through meta-analysis. Although
there has been some debate on how much of total her-
itability could be explained by GWAS data [7], the
common agreement is that both common and rare var-
iants contribute to complex diseases. It is potentially
helpful to add GWAS data into WGS in order to
increase the power. Our results show that both
attempts are promising.
At the same time, several future works could be con-
sidered based on the limitations of the current study.
First, the sample size is likely still small for either veri-
fying asymptotical results or larger power of detecting
weak genetic effects simulated in the data. It would be
nice to further confirm the patterns of comparisons
among these association methods by simulated and
real data with much larger sample size. Second, gene-
based collapsing can be applied as an alternative to the
window scheme used here. Third, we have applied a
simple rare variant collapsing process by direct sum-
ming the genotypes. This collapsing strategy is less
sophisticated than the weighting strategy of SKAT. In
fact, GOFT can further incorporate more successful
collapsing strategies to improve its power, for example,
by weighting the SNPs, like what SKAT and other
methods have adopted [14-17]. Lastly, GOFT repre-
sents a first-stage analysis, which only seeks to answer
where the associations are located; additional analyses
could be required to determine the number and exact
location of causal signals.
Conclusions
We adopted a GOFT to WGS data analysis for detecting
disease-associated genomic segments, and compared it
to the SKAT by using the GAW18 simulation data with
SBP_1 as response. Even without a sophisticated weight-
ing scheme, in many cases, GOFT is comparable to or
better than SKAT with the best weighting scheme.
GOFT can be applied to a combination of GWAS and
WGS data. Our results show that such meta-analysis
has the potential to provide higher power over WGS
data analysis only. In all cases, the power is still low for
detecting overall heritability under the sample size of
142 independent individuals for genetic association
study.
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